Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

Open in Screener

BEAM

Beam Therapeutics Inc

Jan 09 • 11:07AM ET

27.93

-0.07 -0.26 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA EDIT ALNY SRPT SGMO BLUE CLLS VYGR ADVM

| Held by: ARKK XBI VTI IWM ARKG VB VBK VXF IWO IBB

Index	RUT	P/E	-	EPS (ttm)	-4.43	Insider Own	9.75%	Shs Outstand	101.36M	Perf Week	2.90%
Market Cap	2.83B	Forward P/E	-	EPS next Y	-4.65	Insider Trans	-1.07%	Shs Float	91.58M	Perf Month	5.47%
Enterprise Value	1.91B	PEG	-	EPS next Q	-1.01	Inst Own	93.02%	Short Float	21.61%	Perf Quarter	0.21%
Income	-414.64M	P/S	50.88	EPS this Y	5.49%	Inst Trans	-2.01%	Short Ratio	9.41	Perf Half Y	31.98%
Sales	55.70M	P/B	2.93	EPS next Y	-7.36%	ROA	-33.41%	Short Interest	19.79M	Perf YTD	0.75%
Book/sh	9.53	P/C	2.64	EPS next 5Y	-1.05%	ROE	-47.19%	52W High	35.25 -20.77%	Perf Year	3.13%
Cash/sh	10.59	P/FCF	-	EPS past 3/5Y	7.43% -20.88%	ROIC	-37.53%	52W Low	13.52 106.49%	Perf 3Y	-32.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	7.00% 412.30%	Gross Margin	60.38%	Volatility	7.52% 5.41%	Perf 5Y	-66.41%
Dividend TTM	-	EV/Sales	34.30	EPS Y/Y TTM	-157.71%	Oper. Margin	-837.12%	ATR (14)	1.57	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.02	Sales Y/Y TTM	-84.07%	Profit Margin	-744.41%	RSI (14)	55.80	Recom	1.39
Dividend Gr. 3/5Y	- -	Current Ratio	6.02	EPS Q/Q	6.31%	SMA20	1.71%	Beta	2.12	Target Price	44.69
Payout	-	Debt/Eq	0.16	Sales Q/Q	-32.03%	SMA50	10.38%	Rel Volume	0.46	Prev Close	28.00
Employees	483	LT Debt/Eq	0.14	Earnings	Nov 04 BMO	SMA200	31.77%	Avg Volume	2.10M	Price	27.93
IPO	Feb 06, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.99% -14.46%	Trades		Volume	275,273	Change	-0.26%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-09-25	Initiated	Jefferies	Buy	$41
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy	$42
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$40
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$27 → $39
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy	$80
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight	$38 → $40
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$35
Dec-08-23	Downgrade	Jefferies	Buy → Hold	$75 → $30
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform	$75 → $20
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Mar-21-23	Initiated	Bernstein	Mkt Perform	$37
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$62
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$61 → $66
Dec-13-22	Initiated	Citigroup	Buy	$62
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$41
Apr-28-22	Initiated	Credit Suisse	Neutral	$62
Jan-05-22	Initiated	Guggenheim	Buy	$130
Oct-19-21	Initiated	SVB Leerink	Outperform	$117

Show Previous Ratings

Jan-06-26 07:06AM	Three Genomics Stocks Worth Tracking This Year (Zacks) +5.59%
Jan-05-26 12:23PM	ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure (GuruFocus.com)
Dec-31-25 09:32AM	Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? (Zacks)
06:26AM	Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab (GuruFocus.com)
Dec-30-25 11:46PM	Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene (Insider Monkey)
07:33AM	Loading…
07:33AM	Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? (Insider Monkey)
Dec-29-25 12:51PM	TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock (GuruFocus.com)
Dec-22-25 06:50AM	BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy (Insider Monkey) +5.08%
Dec-18-25 04:01PM	Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-25 11:30AM	Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-09-25 11:57AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Dec-06-25 08:00AM	Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-04-25 11:30AM	Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report? (Zacks) +8.12%
Nov-28-25 09:59AM	Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? (Zacks)
Nov-27-25 08:15AM	BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? (Zacks)
10:19AM	Loading…
Nov-21-25 10:19AM	NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks) +7.82%
Nov-14-25 08:58AM	Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? (Zacks)
Nov-12-25 07:31AM	Cathie Wood Dumps $2.4 Million Worth Of Tesla Shares, Doubles Down On These AI Stocks (Benzinga)
07:00AM	Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference (GlobeNewswire)
Nov-10-25 08:16PM	Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results (Insider Monkey)
Nov-05-25 10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
10:41AM	Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
10:30AM	Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles (Zacks)
Nov-04-25 03:37PM	Cathie Wood unloads $7.69 million in top AI stock (TheStreet) -6.23%
03:37PM	Cathie Wood sells another $7.69 million in leading AI stock (TheStreet)
11:43AM	ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
08:35AM	Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates (GlobeNewswire)
Nov-03-25 10:11AM	Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? (Zacks)
09:00AM	Loading…
09:00AM	Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-25 01:45PM	Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates (Zacks) +5.08%
01:44PM	AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues (Zacks)
10:37AM	ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales (Zacks)
Oct-30-25 12:08PM	Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down (Zacks)
Oct-29-25 11:24AM	United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark (Zacks) -6.28%
11:18AM	RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down (Zacks)
09:55AM	Beam Therapeutics (BEAM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Oct-28-25 11:44AM	Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-20-25 09:55AM	Beam Therapeutics Inc. (BEAM)'s Technical Outlook is Bright After Key Golden Cross (Zacks) +17.86%
09:25AM	Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition? (Zacks)
Oct-17-25 09:55AM	Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 76.15%: Read This Before Placing a Bet (Zacks)
09:40AM	Is Beam Therapeutics (BEAM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-11-25 10:02AM	Jim Cramer on Beam Therapeutics: "That's the Speculative Bottom There" (Insider Monkey)
Oct-08-25 12:57AM	What Does Wall Street Think About Beam Therapeutics (BEAM)? (Insider Monkey) +7.44%
Oct-07-25 08:28PM	Lightning Round: Shopify is going much higher, says Jim Cramer (CNBC TV)
Sep-18-25 11:35AM	3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025 (Zacks) +11.80%
Sep-17-25 02:18PM	H.C. Wainwright Maintains Buy on Beam (BEAM), $80 Target on Pipeline Momentum (Insider Monkey)
Sep-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report? (Zacks)
Aug-29-25 10:22AM	Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? (Zacks)
Aug-28-25 08:48AM	CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now? (Zacks)
Aug-25-25 07:00AM	Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences (GlobeNewswire)
Aug-21-25 11:15AM	CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock (Zacks)
Aug-20-25 12:13AM	JonesTrading Reduces the PT on Beam Therapeutics (BEAM), Keeps a Buy Rating (Insider Monkey)
Aug-14-25 07:00AM	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease (GlobeNewswire)
Aug-12-25 11:40AM	Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? (Zacks)
Aug-06-25 11:51AM	BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark (Zacks)
Aug-05-25 08:15AM	Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Jul-30-25 10:00AM	Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
Jul-29-25 10:00AM	Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know (Zacks)
Jul-16-25 09:38AM	Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company (Insider Monkey)
Jul-09-25 10:45AM	Innovation ETF (ARKK) Hits New 52-Week High (Zacks) +5.71%
Jul-06-25 04:15AM	H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT (Insider Monkey)
Jul-03-25 09:18AM	Beam Therapeutics' BEAM-101 Shows Promising Results in Sickle Cell Disease Trial (Insider Monkey)
Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
Jun-20-25 04:08PM	The FDA Shake-Up Continues, And Could Impact Genetic Medicines (Investor's Business Daily)
Jun-19-25 07:22AM	Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? (Zacks)
Jun-18-25 09:35AM	Gene-Editing Stocks Gain on LLY-VERV Deal Announcement (Zacks)
Jun-17-25 04:06PM	Verve Therapeutics Skyrockets Pulling Gene-Editing Stocks Higher On $1.3 Billion Eli Lilly Takeover (Investor's Business Daily)
Jun-13-25 07:00AM	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
Jun-11-25 10:33AM	CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? (Zacks)
Jun-05-25 11:30AM	Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 10:58AM	BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy (Zacks)
08:55AM	Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? (Zacks)
Jun-03-25 07:00AM	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease (GlobeNewswire)
May-29-25 11:54PM	FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)' AATD Gene Therapy (Insider Monkey)
04:01PM	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
May-21-25 09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
May-14-25 09:30AM	Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
May-13-25 07:00AM	Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-12-25 04:01PM	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
May-09-25 01:29PM	Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging (Zacks)
12:41PM	Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates (Zacks)
12:25PM	Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up (Zacks)
11:12AM	Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates (Zacks)
10:41AM	RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
08:55AM	NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up (Zacks)
08:06AM	Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut (Zacks)
May-08-25 12:38PM	Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains (Zacks) +6.32%
12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks)
12:07PM	Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
10:58AM	Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:43AM	Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
10:40AM	Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks)
May-07-25 08:59AM	BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates (Zacks)
May-06-25 05:05PM	Why Beam Therapeutics Stock Tanked on Tuesday (Motley Fool) -19.32%
01:37PM	Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down (Zacks)
11:07AM	Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised (Zacks)

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Emany Sravan Kumar	Chief Financial Officer	Dec 31 '25	Sale	27.10	6,294	170,567	73,706	Jan 05 04:16 PM
Bellon Christine	Chief Legal Officer	Dec 31 '25	Sale	27.10	1,254	33,983	115,667	Jan 05 04:12 PM
FMR LLC	See Remark 1	Oct 27 '25	Sale	26.68	459	12,246	14	Oct 29 01:13 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Oct 01 '25	Sale	24.53	467	11,456	44,045	Oct 03 04:15 PM
Bellon Christine	Chief Legal Officer	Oct 01 '25	Sale	24.53	373	9,150	116,921	Oct 03 04:10 PM
Evans John M.	CEO	Oct 01 '25	Option Exercise	0.67	25,000	16,750	1,011,667	Oct 03 04:05 PM
Evans John M.	CEO	Oct 02 '25	Option Exercise	0.67	25,000	16,750	1,011,667	Oct 03 04:05 PM
Evans John M.	CEO	Oct 02 '25	Sale	24.63	25,000	615,668	986,667	Oct 03 04:05 PM
Evans John M.	CEO	Oct 01 '25	Sale	24.51	25,000	612,655	986,667	Oct 03 04:05 PM
JOHN M EVANS	Officer	Oct 02 '25	Proposed Sale	24.63	25,000	615,668		Oct 02 04:23 PM
JOHN M EVANS	Officer	Oct 01 '25	Proposed Sale	24.51	25,000	612,655		Oct 01 04:12 PM
FMR LLC	See Remark 1	Jul 30 '25	Sale	20.50	48,374	991,667	2,073,665	Aug 01 09:36 AM
Simon Amy	Chief Medical Officer	Jul 03 '25	Sale	20.12	876	17,625	64,864	Jul 03 05:30 PM
Simon Amy	Chief Medical Officer	Jul 01 '25	Sale	16.94	374	6,336	65,740	Jul 03 05:30 PM
Bellon Christine	Chief Legal Officer	Apr 01 '25	Sale	18.35	5,674	104,122	117,294	Apr 03 09:53 PM
Evans John M.	CEO	Apr 01 '25	Sale	18.35	30,663	562,684	986,249	Apr 03 09:52 PM
Ciaramella Giuseppe	President	Apr 01 '25	Sale	18.35	7,434	136,418	190,216	Apr 03 09:51 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Apr 01 '25	Sale	18.35	3,015	55,330	44,512	Apr 03 09:50 PM
Simon Amy	Chief Medical Officer	Apr 02 '25	Sale	17.73	20,997	372,294	65,742	Apr 03 09:50 PM
Simon Amy	Chief Medical Officer	Apr 01 '25	Sale	18.35	9,566	175,542	86,739	Apr 03 09:50 PM
AMY SIMON	Officer	Apr 02 '25	Proposed Sale	17.73	20,997	372,294		Apr 02 04:08 PM
AMY SIMON	Officer	Apr 01 '25	Proposed Sale	22.21	30,562	678,782		Mar 31 06:44 PM
JOHN M. EVANS	Officer	Apr 01 '25	Proposed Sale	22.21	64,842	1,440,141		Mar 31 06:43 PM
CHRISTINE BELLON	Officer	Apr 01 '25	Proposed Sale	22.21	18,125	402,556		Mar 31 06:43 PM
GIUSEPPE CIARAMELLA	Officer	Apr 01 '25	Proposed Sale	22.21	23,750	527,488		Mar 31 06:43 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Feb 18 '25	Sale	35.00	6,287	220,045	37,527	Feb 20 04:10 PM
Bellon Christine	Chief Legal Officer	Feb 14 '25	Option Exercise	7.22	10,000	72,200	112,968	Feb 19 04:10 PM
Bellon Christine	Chief Legal Officer	Feb 14 '25	Sale	34.00	10,000	340,000	102,968	Feb 19 04:10 PM
CHRISTINE BELLON	Officer	Feb 14 '25	Proposed Sale	34.00	10,000	340,000		Feb 14 04:06 PM
Evans John M.	CEO	Jan 30 '25	Sale	26.75	30,000	802,484	908,659	Feb 03 04:05 PM
JOHN M EVANS	Officer	Jan 30 '25	Proposed Sale	26.75	30,000	802,482		Jan 30 04:12 PM

IRWD Ironwood Pharmaceuticals Inc daily Stock Chart

Peers: ABBV VRTX ALNY GILD INCY NBIX REGN BIIB BMY EXEL

| Held by: IWM VTI FNDA VXF IWO IBB XBI VTWO SCHA FESM

Index	RUT	P/E	25.10	EPS (ttm)	0.15	Insider Own	3.68%	Shs Outstand	162.68M	Perf Week	-9.25%
Market Cap	630.38M	Forward P/E	5.24	EPS next Y	0.74	Insider Trans	-0.90%	Shs Float	156.69M	Perf Month	7.34%
Enterprise Value	1.09B	PEG	-	EPS next Q	-0.07	Inst Own	91.68%	Short Float	4.68%	Perf Quarter	118.93%
Income	29.48M	P/S	1.86	EPS this Y	850.00%	Inst Trans	1.87%	Short Ratio	1.83	Perf Half Y	415.09%
Sales	338.99M	P/B	-	EPS next Y	678.95%	ROA	7.51%	Short Interest	7.33M	Perf YTD	14.99%
Book/sh	-1.62	P/C	4.49	EPS next 5Y	-	ROE	-	52W High	5.78 -32.96%	Perf Year	-14.46%
Cash/sh	0.86	P/FCF	9.32	EPS past 3/5Y	-88.04% -47.49%	ROIC	22.45%	52W Low	0.53 635.15%	Perf 3Y	-68.55%
Dividend Est.	-	EV/EBITDA	7.38	Sales past 3/5Y	-5.30% -3.89%	Gross Margin	99.44%	Volatility	14.99% 8.34%	Perf 5Y	-65.34%
Dividend TTM	-	EV/Sales	3.21	EPS Y/Y TTM	1236.48%	Oper. Margin	42.92%	ATR (14)	0.39	Perf 10Y	-60.06%
Dividend Ex-Date	-	Quick Ratio	1.13	Sales Y/Y TTM	-10.42%	Profit Margin	8.70%	RSI (14)	57.04	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	1.13	EPS Q/Q	906.14%	SMA20	7.56%	Beta	0.17	Target Price	6.23
Payout	0.00%	Debt/Eq	-	Sales Q/Q	33.26%	SMA50	21.05%	Rel Volume	0.65	Prev Close	3.98
Employees	253	LT Debt/Eq	-	Earnings	Nov 10 BMO	SMA200	148.40%	Avg Volume	4.01M	Price	3.88
IPO	Feb 03, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	117.60% 63.38%	Trades		Volume	747,613	Change	-2.64%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$8
Apr-15-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-15-25	Downgrade	Jefferies	Buy → Hold
Apr-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Sep-09-24	Initiated	Leerink Partners	Market Perform	$5
Aug-08-24	Downgrade	CapitalOne	Overweight → Equal Weight	$12 → $4
Jan-17-24	Initiated	Craig Hallum	Buy	$21
Dec-14-23	Initiated	Wells Fargo	Overweight	$20
Nov-09-23	Initiated	Jefferies	Buy	$21
Sep-28-23	Initiated	JMP Securities	Mkt Outperform	$22
Sep-02-22	Initiated	CapitalOne	Overweight	$15
Apr-22-22	Initiated	Piper Sandler	Overweight	$16
Sep-30-20	Downgrade	Wells Fargo	Overweight → Equal Weight	$14 → $9
Jun-17-20	Initiated	Northland Capital	Outperform	$14
Jul-10-19	Resumed	Credit Suisse	Neutral
Mar-27-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-25-19	Upgrade	H.C. Wainwright	Sell → Neutral	$14
Jan-24-19	Upgrade	JP Morgan	Underweight → Neutral
Nov-07-18	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-18	Downgrade	Credit Suisse	Outperform → Neutral

Show Previous Ratings

Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
Jan-07-26 03:25PM	Ironwood Pharmaceuticals' 2026 Guidance Shock Sparks a Major Re-Rating (MarketBeat) -5.12%
08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-05-26 10:28AM	Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026 (Zacks) +7.49%
Jan-03-26 07:20AM	Ironwood backs FY25 revenue view $290M-$310M, consensus $306.97M (TipRanks)
07:20AM	Loading…
07:20AM	Ironwood sees FY26 revenue $450M-$475M, consensus $319.47M (TipRanks)
Jan-02-26 12:21PM	Ironwood Pharmaceuticals Stock Soars as Drug-Price Cut Boosts Prospects for 2026 (Barrons.com) +26.71%
07:05AM	Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance (Business Wire)
Dec-10-25 11:30AM	Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report? (Zacks)
Nov-28-25 10:11AM	Ironwood (IRWD) Skyrockets 23% as Govt Price for Linzess Falls Within Expectations (Insider Monkey) -9.33%
Nov-27-25 11:58AM	IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick? (Zacks)
Nov-21-25 10:30AM	Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3? (Zacks)
Nov-13-25 10:36AM	IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks) +8.36%
Nov-11-25 09:56AM	IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars (Zacks) +14.23%
Nov-10-25 08:25AM	Ironwood Pharmaceuticals (IRWD) Q3 Earnings and Revenues Surpass Estimates (Zacks) +31.77%
07:21AM	Loading…
07:21AM	Ironwood: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance (Business Wire)
Nov-06-25 07:35AM	Former blockbuster Linzess grows label with paediatric IBS-C approval (Pharmaceutical Technology)
Nov-05-25 05:35PM	Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +10.16%
Oct-20-25 09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? (Zacks) +7.69%
Oct-16-25 07:56AM	BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Oct-15-25 09:17AM	Teladoc Health Expands Clarity Platform With Workplace Safety Tool (Zacks) +8.78%
06:19AM	Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics (Zacks)
Oct-14-25 10:57AM	5 Small Drug Stocks to Buy as the Industry Shows Some Recovery (Zacks)
09:50AM	Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term (Zacks)
Sep-22-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Aug-21-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks) +7.27%
Aug-08-25 10:36AM	IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates (Zacks)
Aug-07-25 08:25AM	Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates (Zacks) +9.32%
07:26AM	Ironwood: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	Loading…
07:05AM	Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance (Business Wire)
Jun-06-25 11:31AM	Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report? (Zacks) +6.58%
May-08-25 09:55AM	IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates (Zacks) -11.63%
May-07-25 08:20AM	Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -14.55%
07:26AM	Ironwood: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	Ironwood Pharmaceuticals Reports First Quarter 2025 Results (Business Wire)
May-06-25 10:00AM	Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
May-05-25 07:15AM	Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-03-25 10:24PM	The 1-Minute Market Report May 4, 2025 (Seeking Alpha)
May-01-25 10:01AM	Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-30-25 04:25PM	Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference (Business Wire)
Apr-28-25 10:25AM	The 1-Minute Market Report April 27, 2025 (Seeking Alpha) +9.23%
Apr-25-25 07:05AM	Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance (Business Wire)
Apr-22-25 04:05PM	Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support (Business Wire) +7.66%
Apr-16-25 01:07PM	Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News (Zacks)
Apr-15-25 09:18AM	Ironwood Shares Tank on Regulatory Update for Apraglutide (Zacks) +11.47%
07:12AM	Ironwoods shares sink as FDA demands new trial for lead drug (Pharmaceutical Technology)
Apr-14-25 07:00AM	Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide (Business Wire) -31.48%
Apr-13-25 10:44AM	The 1-Minute Market Report April 13, 2025 (Seeking Alpha)
Apr-10-25 10:49AM	Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth (Seeking Alpha)
09:25AM	Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? (Insider Monkey)
Apr-01-25 10:28AM	Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? (Zacks)
Mar-31-25 08:05AM	The 1-Minute Market Report March 30, 2025 (Seeking Alpha)
Mar-27-25 04:05PM	Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing (Business Wire)
Mar-25-25 11:08AM	Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? (Zacks)
Mar-02-25 12:24PM	Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-28-25 02:14AM	Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ... (GuruFocus.com)
Feb-27-25 11:20PM	Q4 2024 Ironwood Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -5.26%
08:15AM	Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates (Zacks)
07:20AM	Ironwood: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance (Business Wire)
Feb-26-25 08:13AM	Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-20-25 04:00PM	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call (Business Wire)
Feb-05-25 06:28PM	Millrose Properties Set to Join S&P SmallCap 600 (PR Newswire) -8.06%
Jan-29-25 04:05PM	Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future (Business Wire) -38.17%
Jan-18-25 08:20AM	Ozempic, Xtandi among next 15 drugs selected for U.S. price talks (TipRanks)
Dec-20-24 09:15AM	Heres Why Brown Capital Management Small Company Fund Sold Ironwood Pharmaceuticals (IRWD) (Insider Monkey) +14.69%
Nov-26-24 04:01PM	Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference (Business Wire) +5.07%
Nov-13-24 04:01PM	Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference (Business Wire)
Nov-08-24 04:01AM	Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... (GuruFocus.com) +6.44%
Nov-07-24 08:15AM	Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates (Zacks) -7.54%
07:20AM	Ironwood: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Third Quarter 2024 Results (Business Wire)
Nov-06-24 07:29AM	Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com) +12.25%
Oct-28-24 07:00AM	Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024 (Business Wire)
Oct-24-24 04:00PM	Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call (Business Wire)
Oct-16-24 01:06PM	State Street Corp's Strategic Acquisition of Ironwood Pharmaceuticals Shares (GuruFocus.com)
08:58AM	Is Ironwood Pharmaceuticals, Inc. (IRWD) the Penny Stock with the Biggest Upside Potential According to Analysts? (Insider Monkey)
Oct-09-24 05:36PM	Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Highlights: Strong LINZESS Demand ... (GuruFocus.com)
Sep-17-24 08:40AM	Implied Volatility Surging for Ironwood (IRWD) Stock Options (Zacks)
Sep-01-24 10:26PM	Ironwood Pharmaceuticals, Inc. (IRWD): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey) +7.58%
04:01PM	Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference (Business Wire)
Aug-09-24 10:56AM	Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates (Zacks)
Aug-08-24 08:15AM	Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2 (Zacks) -32.61%
07:16AM	Ironwood: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ironwood Pharmaceuticals Reports Second Quarter 2024 Results (Business Wire)
Aug-01-24 10:01AM	Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q2 Earnings Expected to Decline (Zacks)
Jul-25-24 04:00PM	Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call (Business Wire)
Jul-17-24 08:30AM	Implied Volatility Surging for Ironwood Pharmaceuticals (IRWD) Stock Options (Zacks)
Jul-08-24 07:00AM	Memo Therapeutics AG appoints Paul Carter as Chairperson (GlobeNewswire)
Jun-12-24 07:00PM	Insider Sale: Director Julie Mchugh Sells Shares of Ironwood Pharmaceuticals Inc (IRWD) (GuruFocus.com) -6.27%
Jun-10-24 07:00PM	Insider Sale: Director Catherine Moukheibir Sells 80,000 Shares of Ironwood Pharmaceuticals Inc ... (GuruFocus.com)
May-30-24 04:01PM	Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 06:00AM	Ironwood Late-Breaker Oral Presentation at Digestive Disease Week Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) (Business Wire) +5.61%
May-10-24 01:58PM	Ironwood Pharmaceuticals Reports Mixed Q1 2024 Results Amid Key Clinical Advancements (GuruFocus.com)
12:59PM	Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:16AM	Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks)
May-09-24 03:59PM	Sector Update: Health Care Stocks Higher Late Afternoon (MT Newswires) -17.00%
01:55PM	Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading (MT Newswires)

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Silver Ronald	Principal Accounting Officer	Jan 05 '26	Sale	4.60	35,416	162,914	276,809	Jan 07 04:05 PM
RONALD SILVER	Officer	Jan 05 '26	Proposed Sale	4.27	35,416	151,226		Jan 05 04:41 PM
Gaskins Tammi L	Chief Commercial Officer	Nov 17 '25	Sale	3.32	6,016	19,973	235,264	Nov 19 04:05 PM
Gaskins Tammi L	Officer	Nov 17 '25	Proposed Sale	3.37	6,324	21,312		Nov 14 04:05 PM
Gaskins Tammi L	Chief Commercial Officer	Aug 11 '25	Sale	0.84	1,316	1,105	241,280	Aug 13 04:05 PM
John Minardo	Chief Legal Officer	Aug 11 '25	Sale	0.84	7,754	6,513	400,378	Aug 13 04:05 PM
Martini Gregory S.	Chief Financial Officer	Aug 11 '25	Sale	0.84	1,265	1,063	182,545	Aug 13 04:05 PM
Silver Ronald	Principal Accounting Officer	Aug 11 '25	Sale	0.84	2,846	2,391	276,809	Aug 13 04:05 PM
John Minardo	Officer	Aug 11 '25	Proposed Sale	0.88	8,281	7,287		Aug 08 04:10 PM
Martini Gregory S.	Officer	Aug 11 '25	Proposed Sale	0.88	1,351	1,189		Aug 08 04:09 PM
Gaskins Tammi L	Officer	Aug 11 '25	Proposed Sale	0.88	1,406	1,237		Aug 08 04:08 PM
MCCOURT Thomas A	Chief Executive Officer	May 16 '25	Sale	0.58	13,353	7,745	1,147,281	May 20 04:14 PM
Gaskins Tammi L	Chief Commercial Officer	May 16 '25	Sale	0.58	2,563	1,487	242,596	May 20 04:10 PM
MCCOURT Thomas A	Officer	May 19 '25	Proposed Sale	0.59	14,661	8,650		May 16 04:07 PM
Gaskins Tammi L	Officer	May 19 '25	Proposed Sale	0.59	2,814	1,660		May 16 04:05 PM
MCCOURT Thomas A	Chief Executive Officer	Feb 10 '25	Sale	1.76	139,064	244,753	1,160,634	Feb 12 09:00 PM
Silver Ronald	Principal Accounting Officer	Feb 10 '25	Sale	1.76	12,048	21,204	279,655	Feb 12 09:00 PM
Shetzline Michael	SVP, CMO, Head-Res&Drug	Feb 10 '25	Sale	1.76	41,269	72,633	554,007	Feb 12 09:00 PM
John Minardo	Chief Legal Officer	Feb 10 '25	Sale	1.76	38,938	68,531	408,132	Feb 12 09:00 PM
Martini Gregory S.	Chief Financial Officer	Feb 10 '25	Sale	1.76	12,052	21,212	183,810	Feb 12 09:00 PM
MCCOURT Thomas A	Officer	Feb 10 '25	Proposed Sale	1.94	142,454	276,361		Feb 07 04:21 PM
Shetzline Michael	Officer	Feb 10 '25	Proposed Sale	1.94	42,274	82,012		Feb 07 04:20 PM
John Minardo	Officer	Feb 10 '25	Proposed Sale	1.94	39,889	77,385		Feb 07 04:18 PM
Martini Gregory S.	Officer	Feb 10 '25	Proposed Sale	1.94	12,347	23,953		Feb 07 04:17 PM

BEAM

Beam Therapeutics Inc

IRWD

Ironwood Pharmaceuticals Inc

Upgrade your FINVIZ experience